{
    "clinical_study": {
        "@rank": "92253", 
        "arm_group": [
            {
                "arm_group_label": "Primed Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects 17 to 48 months who previously received 2 doses of FLU D-QIV vaccine in the primary study (115345)."
            }, 
            {
                "arm_group_label": "Unprimed Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects 17 to 48 months who previously received 2 doses of non-influenza vaccine comparator(s)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and immunogenicity of GSK Biologicals'\n      investigational vaccine GSK2321138A in children who previously participated in study 115345\n      (FLU D-QIV-004 PRI) (NCT01439360)."
        }, 
        "brief_title": "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who the investigator believes that parent(s)/LAR(s) can and will comply with\n             the requirements of the protocol.\n\n          -  Children, male or female who received a 2-dose vaccination in the study 115345\n             (NCT01439360).\n\n          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.\n\n          -  Subjects in stable health as determined by medical history and clinical examination\n             before entering into the study.\n\n        Exclusion Criteria:\n\n          -  Child in care.\n\n          -  Use of any investigational or non-registered product (drug or vaccine) other than the\n             study vaccines within 30 days preceding the first dose of study vaccine, or planned\n             use during the study period.\n\n          -  Since the start of study 115345 (NCT01439360), receipt of any seasonal influenza\n             vaccine other than the study vaccines of study 115345 or planned administration of\n             any influenza vaccine other than the study vaccine during the study.\n\n          -  Administration of any vaccine not foreseen by the study protocol within 4 weeks\n             preceding the first dose of study vaccine or planned use until Visit 2.\n\n          -  Laboratory confirmed influenza infection outside of the 115345 (NCT01439360) study.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history and physical examination.\n\n          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other\n             immune-modifying drugs within 6 months prior to enrolment in the study or planned\n             administration during the study period. Inhaled and topical steroids are allowed.\n\n          -  Administration of immunoglobulins and/ or any blood products within 3 months\n             preceding the first dose of study vaccine or planned administration during the study\n             period.\n\n          -  History of any reaction or hypersensitivity likely to be exacerbated by any component\n             of the vaccine.\n\n          -  Any contraindication to intramuscular injection.\n\n          -  Acute disease and/or fever at the time of enrollment:\n\n               -  Fever is defined as temperature \u2265 37.5\u00b0C by any route.\n\n               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory\n                  infection) without fever may be enrolled at the discretion of the investigator.\n\n          -  Any other condition which, in the opinion of the Investigator, prevents the subject\n             from participating in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "48 Months", 
            "minimum_age": "17 Months"
        }, 
        "enrollment": {
            "#text": "468", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702454", 
            "org_study_id": "116023", 
            "secondary_id": "2012-001230-34"
        }, 
        "intervention": {
            "arm_group_label": [
                "Primed Group", 
                "Unprimed Group"
            ], 
            "description": "1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status", 
            "intervention_name": "Influenza vaccine GSK2321138A", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "GSK Biologicals quadrivalent influenza vaccine", 
            "Influenza", 
            "Children", 
            "Safety", 
            "Immunogenicity"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Decin", 
                        "country": "Czech Republic", 
                        "zip": "405 01"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jindrichuv Hradec", 
                        "country": "Czech Republic", 
                        "zip": "37701"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lipnik nad Becvou", 
                        "country": "Czech Republic", 
                        "zip": "75131"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nachod", 
                        "country": "Czech Republic", 
                        "zip": "547 01"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odolena voda", 
                        "country": "Czech Republic", 
                        "zip": "25070"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ostrava - Poruba", 
                        "country": "Czech Republic", 
                        "zip": "70800"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pardubice", 
                        "country": "Czech Republic", 
                        "zip": "532 03"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 6", 
                        "country": "Czech Republic", 
                        "zip": "1600"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tabor", 
                        "country": "Czech Republic", 
                        "zip": "390 02"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Debica", 
                        "country": "Poland", 
                        "zip": "39-200"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Katowice", 
                        "country": "Poland", 
                        "zip": "40-018"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Siemianowice Slaskie", 
                        "country": "Poland", 
                        "zip": "41-103"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Antequera/M\u00e1laga", 
                        "country": "Spain", 
                        "zip": "29200"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Blanes (Girona)", 
                        "country": "Spain", 
                        "zip": "17300"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Castell\u00f3n", 
                        "country": "Spain", 
                        "zip": "12530"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Castell\u00f3n", 
                        "country": "Spain", 
                        "zip": "12004"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Centelles (Barcelona)", 
                        "country": "Spain", 
                        "zip": "08540"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28046"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paiporta, Valencia", 
                        "country": "Spain", 
                        "zip": "46200"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quart de Poblet, Valencia", 
                        "country": "Spain", 
                        "zip": "46930"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago de Compostela", 
                        "country": "Spain", 
                        "zip": "15706"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41014"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46011"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46024"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Austell", 
                        "country": "United Kingdom", 
                        "state": "Cornwall", 
                        "zip": "PL26 7RL"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coventry", 
                        "country": "United Kingdom", 
                        "state": "Warwickshire", 
                        "zip": "CV6 4DD"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belfast", 
                        "country": "United Kingdom", 
                        "zip": "BT7 2EB"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United Kingdom", 
                        "zip": "BS2 8AE"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Exeter", 
                        "country": "United Kingdom", 
                        "zip": "EX2 5DW"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gloucester", 
                        "country": "United Kingdom", 
                        "zip": "GL1 3NN"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SW17 0QT"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oxford", 
                        "country": "United Kingdom", 
                        "zip": "OX3 7LJ"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Southampton", 
                        "country": "United Kingdom", 
                        "zip": "SO16 6YD"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "Poland", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Quadrivalent Seasonal Influenza Candidate Vaccine GSK2321138A, Administered to Children Who Previously Participated in Study 115345", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Spain: Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Poland: Drug Institute for Registration of Medicinal Products", 
                "Czech Republic: State Institute for Drug Control"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Serum Hemagglutination Inhibition (HI)  antibody titres against each of the vaccine strains after 1 dose of FLU D-QIV vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day 0"
            }, 
            {
                "measure": "Serum HI  antibody titres against each of the vaccine strains after 1 dose of FLU D-QIV vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day 7"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702454"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Serum HI antibody titres against each of the vaccine strains after 1 dose of FLU D-QIV vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day 0 and Day 7"
            }, 
            {
                "measure": "Serum neutralising antibody titres and anti-neuraminidase antibody titres against each of the vaccine strains after 1 dose of FLU D-QIV vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day 0 and Day 7"
            }, 
            {
                "measure": "Occurrence of solicited local and general adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "During a 7-day (Day 0 to 6) follow-up period after first vaccination"
            }, 
            {
                "measure": "Occurrence of unsolicited AEs", 
                "safety_issue": "No", 
                "time_frame": "Within 28 days after first vaccination (Day 0 - Day 27)"
            }, 
            {
                "measure": "Occurrence of AEs with Medically Attended Visits (MAV)", 
                "safety_issue": "No", 
                "time_frame": "During the entire study period (Day 0 - Day 179)"
            }, 
            {
                "measure": "Occurrence of serious adverse events (SAEs) and potential immune mediated diseases (pIMDs)", 
                "safety_issue": "No", 
                "time_frame": "During the entire study period (Day 0 - Day 179)"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}